EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

IN VIVO ANALYSIS OF BETULINIC ACID-LOADED CHITOSAN NANOPARTICLES FOR ALZHEIMER’S DISEASE TREATMENT

Anuja K U, Hemnath Elango

Genetics and Molecular Research · 05.08.2026

DOI: 10.4238/0pntyc13 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genetics and Molecular Research, online erschienen am 05.08.2026. Verfasst von Anuja K U und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease is a progressive neurodegenerative disorder associated with oxidative stress, neuronal damage, and cognitive decline. Betulinic acid possesses neuroprotective and antioxidant properties; however, its poor solubility limits therapeutic efficacy. This study focuses on developing chitosan-based nanoparticles to enhance its delivery. To synthesize and evaluate betulinic acid chitosan nanoparticles (BA-C-NPs) for neuroprotective efficacy and safety in an in vivo Alzheimer’s disease model. BA-C-NPs were prepared using ionic gelation with chitosan (0.15–0.5% w/v) and TPP (0.07 0.75% w/v). Particle size (100–300 nm) and morphology were characterized using FE-SEM and HR-TEM. Acute toxicity was assessed at 2000 mg/kg in rats. Alzheimer’s disease was induced using scopolamine (1 mg/kg, i.p.). Animals were divided into control, disease control, Donepezil-treated, and BA-C-NPs-treated groups. Biochemical parameters, hematological indices, and histopathology were evaluated. BA-C-NPs showed no toxicity at 2000 mg/kg. Disease control animals exhibited reduced body weight (~125 g), haemoglobin (~11 mg/dL), RBC (~4.9 ×10⁶/mL), and increased SGOT (~225 U/L) and SGPT (~115 U/L). BA-C-NPs treatment improved body weight (~178 g), haemoglobin (~14 mg/dL), RBC (~5.6 ×10⁶/mL), and reduced SGOT (~180 U/L) and SGPT (~50 U/L). Histopathology showed reduced neuronal degeneration and improved brain architecture. BA-C-NPs demonstrated significant neuroprotective, antioxidant, and hepatoprotective effects with good safety profile, indicating their potential as an effective therapeutic strategy for Alzheimer’s disease.

Zitieren

APA

U, A. K., & Elango, H. (2026). IN VIVO ANALYSIS OF BETULINIC ACID-LOADED CHITOSAN NANOPARTICLES FOR ALZHEIMER’S DISEASE TREATMENT. Genetics and Molecular Research. https://doi.org/10.4238/0pntyc13

Vancouver

U AK, Elango H. IN VIVO ANALYSIS OF BETULINIC ACID-LOADED CHITOSAN NANOPARTICLES FOR ALZHEIMER’S DISEASE TREATMENT. Genetics and Molecular Research. 2026. doi:10.4238/0pntyc13

BibTeX
@article{U2026,
  author = {U, Anuja K and Elango, Hemnath},
  title = {IN VIVO ANALYSIS OF BETULINIC ACID-LOADED CHITOSAN NANOPARTICLES FOR ALZHEIMER’S DISEASE TREATMENT},
  journal = {Genetics and Molecular Research},
  year = {2026},
  doi = {10.4238/0pntyc13}
}
Kostenlos starten →